Jazz Pharmaceuticals’ Q2 2026 results reflect resilience in its oxybate franchise amid ongoing pricing pressures and payor scrutiny typical for orphan drug markets, while integration of recent acquisitions such as Chimerix adds operational complexity. The company’s business model, centered on proprietary specialty pharmaceuticals targeting rare diseases with orphan exclusivity benefits, faces regulatory and reimbursement headwinds. Jazz maintains strong liquidity but carries significant debt from acquisition financing. Near-term performance hinges on effective pipeline advancement, successful assimilation of acquired assets, and navigating evolving U.S. regulatory and pricing landscapes.